Compare Eli Lilly And Co (LLY) vs Upstart Holdings Inc (UPST) Price & Performance

Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.

LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.

Upstart Holdings trades at $24.19, up 0.71% with bearish technical signals despite recent partnership expansions. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though recent quarters show earnings misses. Valuation ratios remain elevated with P/E of 46.52 and P/S of 2.1, while analyst consensus targets $39.50 with mixed sentiment.

The stock faces near-term pressure from technical weakness and earnings volatility, but long-term potential exists through AI-driven lending expansion and new auto/HELOC partnerships. Key risks include credit market sensitivity, rising debt levels, and competitive fintech landscape. Current price near recent lows presents opportunity for patient investors despite operational cash flow challenges.